Two patients (cases #5 and #6) with hormone receptor–positive breast cancer declined the recommended adjuvant hormone therapy: one progressed at 11 months and was alive at 19+ months, and the other continued to be recurrence free at 17+ months of follow-up (Fig. 1). This evidence concerns the gene NR4A1 and breast cancer.